Retifanlimab: all 49 studies that test it
Page 1 of 1. Open to participants first (15), then studies with results posted, then the rest; newest registration first within each.
- Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast CancerNot yet recruitingNCT07772245Phase 2
- Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PCNot yet recruitingNCT07765836Phase 2
- NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal CancerNot yet recruitingNCT07677579Phase 2
- ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1Not yet recruitingNCT07472322Phase 1/2
- Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade GliomasRecruitingNCT07468136Phase 1/2
- ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal CancerRecruitingNCT07425054Phase 2
- Retifanlimab and Ruxolitinib In Solid MalignanciesRecruitingNCT07219576Phase 1/2
- 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)RecruitingNCT06896188Phase 1
- A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered GliomaRecruitingNCT06610682Early Phase 1
- A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)RecruitingNCT06389799Phase 2
- Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid TumorsRecruitingNCT06320405Phase 1/2
- Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent GlioblastomaRecruitingNCT06160206Phase 2
- Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.RecruitingNCT06072612Phase 3
- Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With GlioblastomaRecruitingNCT05083754Phase 1
- Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)RecruitingNCT04374305Phase 2
- 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic AdenocarcinomaTerminatedNCT05239182Phase 2Results posted
- Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck CancerTerminatedNCT04634825Phase 2Results posted
- An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial CarcinomaTerminatedNCT04586244Phase 2Results posted
- Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).CompletedNCT04472429Phase 3Results posted
- Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)CompletedNCT04231981Phase 2Results posted
- Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung CancerCompletedNCT04205812Phase 3Results posted
- INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary CancerCompletedNCT04116073Phase 2Results posted
- Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerCompletedNCT04082364Phase 2/3Results posted
- A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)CompletedNCT03679767Phase 2Results posted
- A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)CompletedNCT03599713Phase 2Results posted
- A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)CompletedNCT03597295Phase 2Results posted
- MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal CancerCompletedNCT03531632Phase 1/2Results posted
- Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory CancerCompletedNCT02475213Phase 1Results posted
- A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)SuspendedNCT06959537Phase 1
- PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCLWithdrawnNCT06290622Phase 1
- Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell CarcinomaActive, not recruitingNCT06056895Phase 2
- Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated GlioblastomaActive, not recruitingNCT05743595Phase 1
- Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to SurgeryActive, not recruitingNCT05594290Phase 2
- Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell LymphomaActive, not recruitingNCT05455697Phase 1/2
- Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT05440942Phase 1
- Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)Active, not recruitingNCT04968106Phase 2
- Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal CancerWithdrawnNCT04799431Phase 1
- Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid SyndromeWithdrawnNCT04776876Phase 2
- PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent ChemoradiotherapyActive, not recruitingNCT04494009Phase 2
- Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.CompletedNCT04463771Phase 2
- INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE StudyActive, not recruitingNCT04445844Phase 2
- Palbociclib and INCMGA00012 in People With Advanced LiposarcomaActive, not recruitingNCT04438824Phase 2
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin MalignancyActive, not recruitingNCT04387084Phase 1
- INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)WithdrawnNCT04203511Phase 3
- Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT04129320Phase 2/3
- A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid TumorsCompletedNCT03910530Phase 1
- MGD009/MGA012 Combination in Relapsed/Refractory CancerCompletedNCT03406949Phase 1
- Combination Study of SV-BR-1-GM With RetifanlimabCompletedNCT03328026Phase 1/2
- A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid TumorsCompletedNCT03059823Phase 1